Lee-may Chen, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Lee-may Chen, MD

Associate Clinical Professor, Department of Obstetrics, Gynecology, and Reproductive Sciences, UCSF
Edward C. Hill, MD, Endowed Chair

Phone: (415) 353-9600 (appts)
Box 1702, UCSF
San Francisco, CA 94143-1702

View on UCSF Profiles

Cancer Center Membership

Associate Member ยป Cancer Genetics

Education

University of Michigan, Ann Arbor, MI, B.S., 1985-1989, Biomedical Sciences
University of Michigan Medical School, Ann Arbor, MI, M.D., 1988-1992, Chinese Studies, Medicine
University of Michigan Hospitals, Ann Arbor, MI, Residency, 1992-1996, Obstetrics & Gynecology
University of California, Los Angeles & Cedars-Sinai Medical Centers, Fellowship, 1996-1999, Gynecologic Oncology
University of California, San Francisco, San Francisco, CA, 2006-2007, Teaching Scholars Program
University of California, San Francisco, San Francisco, CA, 2010, Mentor Development Program


Professional Experience

  • 1999-2007
    Assistant Clinical Professor, Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, & Reproductive Sciences, University of California, San Francisco
  • 2007-2011
    Associate Clinical Professor, Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, & Reproductive Sciences, University of California, San Francisco
  • 2011--present
    Clinical Professor, Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, & Reproductive Sciences, University of California, San Francisco

Honors & Awards

  • 1999
    ASCO/AACR Methods in Clinical Cancer Research Workshop
  • 2001
    Berlex Foundation, Junior Faculty Development Course
  • 2002
    ACOG/CREOG National Faculty Award
  • 2003-2005
    UCSF Department of Obstetrics, Gynecology, and Reproductive Sciences
  • 2007-2008
    Outstanding Resident Teaching Award
  • 2006
    Cancer Liason Physician Outstanding Performance Award
  • 2010
    Helen Diller Family Comprehensive Cancer Center Quality Award
  • 2010
    The Ernie H. Rosenbaum, MD Commitment to Patient Care Award
  • 2010-present
    Edward C. Hill, MD, Endowed Chair

Selected Publications

  1. In response to Peshkin et al. "Genetic counseling and testing for hereditary cancer risk in young adult women: Facilitating autonomy and informed decision making is key". Gynecol Oncol Rep. 2015 Nov; 14:46.
    View on PubMed
  2. Sexual satisfaction and quality of life in survivors of localized cervical and ovarian cancers following fertility-sparing surgery. Gynecol Oncol. 2015 Oct; 139(1):141-7.
    View on PubMed
  3. Inverse Planned High-Dose-Rate Brachytherapy for Locoregionally Advanced Cervical Cancer: 4-Year Outcomes. Int J Radiat Oncol Biol Phys. 2015 Aug 1; 92(5):1093-100.
    View on PubMed
  4. Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study 0229N. Gynecol Oncol. 2015 Jul; 138(1):24-9.
    View on PubMed
  5. Managing symptoms and maximizing quality of life after preventive interventions for cancer risk reduction. Curr Opin Obstet Gynecol. 2015 Feb; 27(1):40-4.
    View on PubMed
  6. Survival differences of Asian and Caucasian epithelial ovarian cancer patients in the United States. Gynecol Oncol. 2015 Mar; 136(3):491-7.
    View on PubMed
  7. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2015 Jan; 136(1):3-7.
    View on PubMed
  8. Survival differences in women with serous tubal, ovarian, peritoneal, and uterine carcinomas. Am J Obstet Gynecol. 2015 Feb; 212(2):188.e1-6.
    View on PubMed
  9. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome. Am J Surg Pathol. 2014 Jun; 38(6):793-800.
    View on PubMed
  10. Early detection of high-grade tubal serous carcinoma in women at low risk for hereditary breast and ovarian cancer syndrome by systematic examination of fallopian tubes incidentally removed during benign surgery. Am J Surg Pathol. 2014 Jun; 38(6):729-42.
    View on PubMed
  11. Disease and treatment characteristics do not predict symptom occurrence profiles in oncology outpatients receiving chemotherapy. Cancer. 2014 Aug 1; 120(15):2371-8.
    View on PubMed
  12. Predictors of high symptom burden in gynecologic oncology outpatients: who should be referred to outpatient palliative care? Gynecol Oncol. 2014 Mar; 132(3):698-702.
    View on PubMed
  13. Ovarian cancer, version 2.2013. J Natl Compr Canc Netw. 2013 Oct 1; 11(10):1199-209.
    View on PubMed
  14. Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study. Clin Cancer Res. 2013 Oct 1; 19(19):5485-93.
    View on PubMed
  15. Prospective multicenter randomized intermediate biomarker study of oral contraceptive versus depo-provera for prevention of endometrial cancer in women with Lynch syndrome. Cancer Prev Res (Phila). 2013 Aug; 6(8):774-81.
    View on PubMed
  16. Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non-clinic-based sample of women in northern California. Cancer. 2013 May 1; 119(9):1652-9.
    View on PubMed
  17. Ovarian cancer, version 3.2012. J Natl Compr Canc Netw. 2012 Nov 1; 10(11):1339-49.
    View on PubMed
  18. Factors associated with publication of plenary presentations at the Society of Gynecologic Oncologists annual meeting. Gynecol Oncol. 2013 Jan; 128(1):128-31.
    View on PubMed
  19. Characteristics of success in mentoring and research productivity - a case-control study of academic centers. Gynecol Oncol. 2012 Apr; 125(1):8-13.
    View on PubMed
  20. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol. 2012 Feb 1; 30(4):372-9.
    View on PubMed

Go to UCSF Profiles, powered by CTSI